Genfit S.A. (GNFTY)

Genfit S.A. (GNFTY) Healthcare & Pipeline Overview

Genfit S.A. is a late-stage biopharmaceutical entity specializing in metabolic and liver diseases, advancing a pipeline that includes Elafibranor for primary biliary cholangitis and the NIS4 diagnostic platform for NASH. Headquartered in France, the company leverages strategic partnerships to develop and commercialize novel therapeutic and diagnostic solutions addressing significant unmet medical needs.

What Is the Investment Thesis for GNFTY?

Genfit S.A. presents an investment thesis centered on its late-stage pipeline addressing significant unmet medical needs in liver and metabolic diseases. The company's lead therapeutic candidate, Elafibranor, is in Phase III trials for primary biliary cholangitis, a critical stage that, if successful, could lead to market authorization and substantial revenue generation. Concurrently, the NIS4 diagnostic platform for NASH and fibrosis, coupled with the licensing agreement with Labcorp for NASHnext, positions Genfit to capitalize on the growing demand for non-invasive diagnostic tools in liver disease. The diversified pipeline, including GNS561 for cholangiocarcinoma in Phase 1b/2a and VS-01 for rare metabolic disorders, offers multiple shots on goal. However, the company's current financial profile, marked by a -127.4% profit margin and its listing on the OTC market, indicates inherent risks associated with early-stage biopharmaceutical development and lower liquidity. Future value drivers are heavily dependent on positive clinical trial outcomes, regulatory approvals, and successful commercialization, which could transform its financial standing from its current $447.83M market capitalization.

Based on FMP financials and quantitative analysis

GNFTY Key Highlights

• Market capitalization stands at $0.45 billion, reflecting its valuation as a late-stage biopharmaceutical company.
• Reported a profit margin of -127.4%, indicative of a company in the research and development phase prior to significant commercial revenue.
• Maintains a gross margin of 26.0%, suggesting some revenue generation, likely from collaborations or early product sales, though overall profitability remains negative.
• The company's stock exhibits a Beta of 1.19, indicating higher volatility compared to the broader market.
• Employs 188 individuals, supporting its extensive research, development, and administrative functions for its diverse pipeline.

Who Are GNFTY's Competitors?

GNFTY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GNFTY's Key Strengths?

• Advanced late-stage pipeline with Elafibranor in Phase III for Primary Biliary Cholangitis, addressing a significant unmet medical need.
• Proprietary NIS4 diagnostic platform for NASH and fibrosis, offering a non-invasive solution with commercialization potential through Labcorp.
• Diversified therapeutic portfolio targeting multiple liver and metabolic disorders, including rare diseases and oncology.
• Strategic collaborations with established partners like Labcorp and Genoscience Pharma, enhancing development and commercialization capabilities.

What Are GNFTY's Weaknesses?

• Significant negative profit margin of -127.4%, indicating ongoing substantial R&D expenses without corresponding commercial revenues.
• Reliance on clinical trial success for future revenue generation, with inherent risks of failure or delays.
• Listing on the OTC market ('OTC Other') implies lower liquidity and less stringent regulatory oversight compared to major exchanges.
• High cash burn typical of a late-stage biopharmaceutical company, necessitating future funding or successful product launches.

What Could Drive GNFTY Stock Higher?

• Successful completion and positive data readout from the Phase III clinical trials for Elafibranor in primary biliary cholangitis.
• Progress and positive interim data from the Phase 1b/2a trials for GNS561 in cholangiocarcinoma, indicating advancement towards later stages.
• Commercialization efforts and market adoption of the NASHnext blood-based molecular diagnostic test through the partnership with Labcorp.
• Advancement of the VS-01 program for Urea Cycle Disorder and Organic Acidemia Disorder into later clinical phases, demonstrating pipeline progression.
• Regulatory submissions and potential approvals for Elafibranor following Phase III completion, opening pathways to market entry.

What Are the Key Risks for GNFTY?

• Financial-distress signal — its Altman Z-Score of -0.17 sits in the distress zone (elevated bankruptcy risk).
• Clinical trial failures or unexpected safety concerns for any of Genfit's pipeline candidates, particularly Elafibranor, could significantly impact future prospects.
• The company's substantial negative profit margin (-127.4%) indicates a high cash burn rate, necessitating successful product commercialization or further capital raises.
• As an OTC Other listed stock, GNFTY faces risks of lower liquidity, less stringent regulatory oversight, and potential difficulty in raising capital.
• Intense competition within the biotechnology sector for treatments of liver and metabolic diseases could limit market share and pricing power for future products.
• Regulatory delays or failure to obtain marketing approval for its drug candidates and diagnostic platforms, even after successful clinical trials.

What Are the Growth Opportunities for GNFTY?

• **Elafibranor for Primary Biliary Cholangitis (PBC):** Genfit's lead candidate, Elafibranor, is currently in Phase III clinical trials for PBC, a chronic, progressive autoimmune liver disease. The global market for PBC treatments is substantial, driven by the need for effective therapies beyond existing options, particularly for patients with inadequate response. A successful outcome in Phase III and subsequent regulatory approval would unlock a significant revenue stream for Genfit, positioning it as a key player in this specialized therapeutic area. The timeline for potential commercialization hinges on trial completion and regulatory review, offering a near-to-medium term growth catalyst.
• **NIS4 Diagnostic Platform for NASH and Fibrosis:** The development of NIS4, a diagnostic platform for nonalcoholic steatohepatitis (NASH) and fibrosis, represents a critical growth opportunity. NASH is a rapidly growing liver disease with no approved non-invasive diagnostic gold standard. The ability to accurately and non-invasively identify NASH and fibrosis early could significantly improve patient management and clinical trial recruitment. The licensing agreement with Labcorp for NASHnext further enhances its commercialization potential, tapping into a large diagnostic market. This platform addresses a substantial unmet need, offering a scalable revenue stream independent of drug sales.
• **VS-01 for Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD):** Genfit's VS-01 program targets Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD), which are rare genetic metabolic conditions. The orphan drug market, while smaller in patient population, often commands premium pricing and offers expedited regulatory pathways. Successful development and approval of VS-01 could provide Genfit with a valuable asset in a niche market with less competition and high patient need. The ongoing development of this candidate represents a strategic diversification of its pipeline into rare diseases.
• **GNS561 for Cholangiocarcinoma (CCA):** GNS561, currently in Phase 1b/2a trials for cholangiocarcinoma (CCA), an aggressive and often fatal bile duct cancer, presents a high-impact growth opportunity. CCA has limited treatment options and a poor prognosis, indicating a significant unmet medical need for novel therapies. Genfit's partnership with Genoscience Pharma for joint development and marketing underscores the potential of this candidate. Positive clinical data and progression through trials could position GNS561 as a critical treatment for this severe cancer, opening up a specialized oncology market segment.
• **Strategic Collaborations and Licensing Agreements:** Genfit's established strategic collaborations, such as the licensing agreement with Labcorp for NASHnext and the partnership with Genoscience Pharma for GNS561, are crucial growth drivers. These collaborations provide access to broader commercialization networks, shared development costs, and external expertise. Such agreements can generate upfront payments, milestone payments, and future royalties, diversifying revenue streams and mitigating R&D risks. Expanding these types of partnerships could accelerate pipeline development and market penetration for its various assets.

What Opportunities Does GNFTY Have?

• Successful completion of Elafibranor's Phase III trials and subsequent regulatory approval, opening a new revenue stream in the PBC market.
• Expansion of the NIS4 diagnostic platform's commercialization and adoption, capitalizing on the growing need for NASH diagnostics.
• Positive clinical outcomes for other pipeline candidates like GNS561 (CCA) or VS-01 (UCD/OAD), diversifying future revenue sources.
• Potential for new strategic partnerships or licensing agreements to further accelerate development or expand market reach for its assets.
• Uplisting to a major stock exchange, which could improve liquidity, investor visibility, and access to capital.

What Threats Does GNFTY Face?

• Clinical trial failures or unexpected adverse events for any of its pipeline candidates, leading to significant delays or discontinuation.
• Intense competition from larger pharmaceutical companies or other biotech firms developing similar treatments for liver and metabolic diseases.
• Regulatory hurdles and stringent approval processes by health authorities, which can delay or prevent market entry.
• Market acceptance and reimbursement challenges for new drugs and diagnostics, even after regulatory approval.
• Economic downturns or changes in healthcare policy impacting R&D funding, drug pricing, or market access.

What Are GNFTY's Competitive Advantages?

• Late-stage clinical pipeline: Elafibranor in Phase III for PBC provides a significant lead in a niche market, representing a high barrier to entry for competitors.
• Proprietary diagnostic platform: The NIS4 platform offers a unique, non-invasive approach to diagnosing NASH and fibrosis, potentially establishing a market advantage.
• Specialized therapeutic focus: Deep expertise and a concentrated pipeline in metabolic and liver diseases allow for focused R&D and market penetration.
• Strategic collaborations: Partnerships with industry leaders like Labcorp and Genoscience Pharma provide access to commercialization infrastructure and shared development resources, enhancing market reach and de-risking development.
• Intellectual property: Patents protecting its drug candidates and diagnostic technologies provide legal exclusivity and a competitive edge.

What Does GNFTY Do?

Genfit S.A., founded in 1999 and headquartered in Loos, France, operates as a late-stage biopharmaceutical enterprise dedicated to the discovery and advancement of novel therapeutic drugs and diagnostic technologies for a range of metabolic and liver-related conditions. The company's strategic focus is on addressing significant unmet medical needs within these therapeutic areas. A cornerstone of its pipeline is Elafibranor, a prominent drug candidate currently undergoing Phase III clinical trials for the treatment of primary biliary cholangitis (PBC), a chronic liver disease. Beyond therapeutics, Genfit is also innovating in diagnostics with NIS4, a proprietary platform engineered to identify nonalcoholic steatohepatitis (NASH) and fibrosis, conditions with a substantial global patient population. The company's diverse portfolio extends to other promising candidates, including VS-01, which is being developed for Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD), rare genetic metabolic conditions. GNS561 is another key asset, currently in Phase 1b/2a trials for cholangiocarcinoma (CCA), an aggressive cancer of the bile ducts. Furthermore, Genfit is exploring a combination of VS-01-ACLF with Nitazoxanide (NTZ) in Phase 1 for acute-on-chronic liver failure, a severe and often fatal condition. Preclinical research is also underway for VS-02-HE, aimed at reducing hyperammonemia and stabilizing blood ammonia, and SRT-015, an ASK1 inhibitor designed to suppress cellular apoptosis, inflammation, and fibrosis. To bolster its development and commercialization efforts, Genfit has forged critical strategic collaborations, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Additionally, the company has partnered with Genoscience Pharma to jointly develop and market the experimental treatment GNS561 for CCA, demonstrating a multifaceted approach to bringing its innovations to market.

What Products and Services Does GNFTY Offer?

• Develops novel therapeutic drugs for metabolic and liver-related conditions.
• Identifies and advances diagnostic technologies, such as the NIS4 platform for NASH and fibrosis.
• Conducts Phase III clinical trials for Elafibranor, a lead candidate for primary biliary cholangitis (PBC).
• Researches and develops treatments for rare metabolic disorders like Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD) with VS-01.
• Explores therapies for aggressive cancers such as cholangiocarcinoma (CCA) with GNS561.
• Engages in preclinical research for conditions like hyperammonemia (VS-02-HE) and cellular apoptosis/inflammation (SRT-015).
• Forms strategic partnerships for the commercialization of diagnostic tests, like NASHnext with Labcorp.
• Collaborates on the joint development and marketing of experimental treatments, such as GNS561 with Genoscience Pharma.

How Does GNFTY Make Money?

• Drug development and potential future sales: Revenues from the commercialization of approved therapeutic drugs for liver and metabolic diseases.
• Diagnostic platform licensing and sales: Income generated from licensing its diagnostic technologies (e.g., NIS4, NASHnext) to partners or direct sales of diagnostic tests.
• Strategic partnerships and collaborations: Revenue from upfront payments, milestone payments, and royalties derived from agreements with pharmaceutical and diagnostic companies.
• Research and development grants: Potential funding from government agencies or non-profit organizations for specific research initiatives.

What Industry Does GNFTY Operate In?

Genfit S.A. operates within the highly specialized and competitive biotechnology industry, specifically targeting metabolic and liver-related conditions. This sector is characterized by significant R&D investment, long development cycles, and high regulatory hurdles, but also by the potential for substantial returns upon successful drug approval. The market for liver diseases, including NASH and PBC, represents a substantial unmet medical need globally, with a growing prevalence driven by lifestyle factors. Genfit's focus on both therapeutics and diagnostics, such as its NIS4 platform and NASHnext collaboration, positions it to address different facets of these complex diseases. Competitively, the landscape includes larger pharmaceutical companies and other biotech firms developing similar treatments. Genfit differentiates itself through its late-stage pipeline assets like Elafibranor and its strategic partnerships, aiming to capture market share in these high-value therapeutic areas.

Who Are GNFTY's Key Customers?

• Patients suffering from metabolic and liver-related conditions, including PBC, NASH, UCD, OAD, and CCA.
• Healthcare providers (physicians, specialists) who prescribe or recommend its therapeutic and diagnostic solutions.
• Pharmaceutical companies seeking partnerships for co-development, licensing, or commercialization of novel treatments.
• Diagnostic laboratories and healthcare systems utilizing its diagnostic tests for disease identification and management.

Company Profile

Genfit S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Loos, FR. The company is led by CEO Pascal Prigent. GNFTY has traded publicly since 2019.

Key Financial Metrics

Return on assets is -54.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.3%, the inverse of the P/E and a quick read on earnings relative to price.

GNFTY Valuation & Market Position

With a $447.83M market cap, Genfit S.A. sits in the small-cap segment of the market. Relative to its peer group, GNFTY's quantitative score of 65/100 is below the peer average of 78/100.

Quarterly Financial Performance: Genfit S.A.

Revenue for Genfit S.A. came in at $31.2M during Q2 2025, a 272.0% improvement versus the preceding quarter. The company recorded a net loss of $9.3M, with diluted EPS of $-0.19. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare.

F-Score 4/9Financial Health

Genfit S.A.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.17 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Genfit S.A. revenue of about $90.9M for fiscal 2026, with EPS near $0.28. The estimate reflects 4 contributing analysts.

GNFTY Financials

GNFTY Latest News

No recent news available for GNFTY.

GNFTY Analyst Consensus

GNFTY MoonshotScore

Common Questions About GNFTY (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources